Zofran and Nephropathy toxic - a phase IV clinical study of FDA data

Summary:

Nephropathy toxic is reported as a side effect among people who take Zofran (ondansetron hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Cisplatin, and have High blood pressure.

The phase IV clinical study analyzes which people have Nephropathy toxic when taking Zofran. It is created by eHealthMe based on reports of 93,713 people who have side effects when taking Zofran from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Nephropathy toxic?

Nephropathy toxic (damage to kidney due to toxins) is found to be associated with 601 drugs and 737 conditions by eHealthMe. Check the latest studies of Nephropathy toxic.

On Jul, 07, 2026

93,713 people reported to have side effects when taking Zofran.
Among them, 30 people (0.03%) have Nephropathy toxic.

Among these 30 people:

How long have people been on Zofran when they have Nephropathy toxic? *

What is the gender of people who have Nephropathy toxic when taking Zofran? *

female: 55.17 %
male: 44.83 %

What is the age of people who have Nephropathy toxic when taking Zofran? *

What are other drugs people take besides Zofran? *

What are other side effects people have besides Nephropathy toxic? *

Acute Kidney Failure: 12 people, 40.00%
Diarrhea: 5 people, 16.67%
Dehydration (dryness resulting from the removal of water): 4 people, 13.33%
Blood Creatinine Increased: 4 people, 13.33%
Pleural Effusion (water on the lungs): 3 people, 10.00%
Hyperkalemia (damage to or disease of the kidney): 3 people, 10.00%
Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body): 3 people, 10.00%
Renal Tubular Necrosis (death of kidney tubules): 3 people, 10.00%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 2 people, 6.67%
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 2 people, 6.67%

What are the existing conditions these people have? *

Pain: 2 people, 6.67%
Synovial Sarcoma (tumour of synovial membrane of joint): 2 people, 6.67%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 6.67%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 6.67%
Multiple Myeloma (cancer of the plasma cells): 2 people, 6.67%
Hiv Infection: 2 people, 6.67%
High Blood Pressure: 2 people, 6.67%
Type 2 Diabetes: 1 person, 3.33%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 3.33%
Endometrial Cancer: 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and have Nephropathy toxic?

- Check whether Nephropathy toxic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zofran:

Zofran (94,987 reports)

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephropathy toxic:

Nephropathy toxic (601 drugs)

Browse all the conditions that are associated with Nephropathy toxic:

Nephropathy toxic (737 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride (the active ingredients of Zofran) and Zofran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.